Adapting Oncology Clinical Research Practices and Therapeutic Development Strategies in the Global COVID-19 Era

Life Sciences, Clinical Trials, Drug Discovery & Development,
  • Tuesday, July 14, 2020 | 10am EDT (NA) / 3pm BST (UK) / 4pm CEST (EU-Central).
  • 60 min

Cancer treatments and research have been severely impacted by the COVID-19 pandemic, and many questions remain about how to balance the management of care with patient safety. To better understand the effect of the disruption, four medical oncology specialists will participate in a unique panel discussion. Join these panelists as they share their thoughts from multiple viewpoints across the globe in this educational discussion that spans industry, academia and patient care perspectives.

First, the panelists will discuss scientific and clinical considerations, sharing how the pandemic has affected their ability to treat patients in clinical practices and trials as well as the impact on clinical trial participation. Following a series of guided questions, they will provide their candid thoughts on the role of virtual tools and technologies in decentralized clinical trials (DCTs) in the post-pandemic era in order to minimize exposure and de-risk trials. They will also discuss the potential of maintaining ongoing collaborations among drug development stakeholders, both within oncology and other therapeutic areas, in the effort to ensure continuity in clinical trials.

The second half of the webinar will focus on the emerging knowledge of SARS-CoV-2 biology. Increasing evidence points to the key role played by inflammation, immune dysfunction and thrombophilia in the pathophysiology of COVID-19. Multiple clinical trials are underway to test repurposed cancer drugs for COVID-19. The panelists will discuss which ones may be most promising and the most efficient ways to advance development.

Register today to join this informative round table discussion and increase your understanding of COVID-19 and its impact on research and treatments for patients with cancer.

This webinar is part of a scientific series Covance is offering focused on trends, opportunities and challenges associated with current and future applications in Oncology. Learn more and register for upcoming webinars on topics such as adoptive T-cell therapies, biomarker technologies for the detection of rare cancer driver mutations and novel targeted therapies and more.

Speakers

http://Kamal%20Veer%20Saini,%20Covance%20Clinical%20Development%20Services

Kamal Veer Saini, MD, Senior Medical Director, Oncology, Covance Clinical Development Services

Dr. Kamal Veer Saini is a board-certified medical oncologist based in Brussels, Belgium. As Senior Medical Director at Covance, he contributes to medical strategy in the oncology area and client consulting and engagement on asset development and all related aspects of medical and scientific execution.

He has more than 15 years of experience in academia and industry, having held numerous posts of increasing seniority across all phases of clinical drug development in various cancer types (solid tumors as well as hematological malignancies) with both regional and global responsibility.

Message Presenter
http://Giuseppe%20Curigliano,%20University%20of%20Milano,%20Head%20of%20the%20Division%20of%20Early%20Drug%20Development%20at%20European%20Institute%20of%20Oncology,%20Italy

Giuseppe Curigliano, MD, PhD, Associate Professor of Medical Oncology at University of Milano, Head of the Division of Early Drug Development at European Institute of Oncology, Italy

Dr. Giuseppe Curigliano is a clinician scientist specializing in early drug development for patients with solid tumors with a special commitment to breast cancer. He has been a Member of the ESMO Breast Cancer Faculty since 2001 and is currently the Faculty Coordinator. He has also served on the Scientific Committee for the St Gallen Conference since 2011, and was the Scientific Chair in St Gallen 2017 and 2019. He served as Co-Scientific Chair for ESMO Breast Congress 2019 and 2020. He has been an Editorial Board Member for Annals of Oncology since 2014, and serves as Co-Editor in Chief of The Breast, Co-Editor in Chief of Cancer Treatment Reviews, Associate Editor of the European Journal of Cancer and Editor of the Journal of Clinical Oncology. He also serves on the European School of Oncology (ESO) faculty committee.

Message Presenter
http://Chris%20Twelves,%20NIHR%20Leeds%20Clinical%20Research%20Facility

Chris Twelves, MD, FRCP, Professor of Clinical Cancer Pharmacology and Oncology, Director of the NIHR Leeds Clinical Research Facility

Dr. Chris Twelves is a medical oncologist with a particular interest in new drug development and clinical pharmacology. His clinical practice has been in colorectal and breast cancer. After training as an oncologist in London he was Senior Lecturer, then Reader, in Medical Oncology in Glasgow at the Beatson Oncology Centre before taking up his current post at the University of Leeds and St James’s Institute of Oncology.

He has been a member of the Cancer Research UK New Agents Committee, Chair of the New Drug Development Group of the EORTC and was Scientific Chair of the Berlin 2009 ECCO-ESMO 34 meeting. He has been involved in the development of several important new agents including capecitabine, and eribulin. Dr. Twelves has a particular interest in early clinical trials and pharmacokinetics including intra-tumoral drug pharmacokinetics and has published over 200 papers and contributed to several books, including one on Phase I clinical trials and another on the design of Phase II clinical trials.

Message Presenter
http://Javier%20de%20Castro%20Carpeño,%20iversity%20of%20Madrid

Javier de Castro Carpeño, MD, Head of the Medical Oncology Section of the La Paz University Hospital in Madrid, Associate Professor of Oncology in the School of Medicine at the Autonomous University of Madrid and Co-Director of the Chair of Innovation Medicine

Dr. Javier de Castro’s main areas of care and scientific interest are focused on the molecular biology of lung cancer and other thoracic tumors, study of predictive factors of response to cancer treatments through high-performance techniques and study of etiopathogenic factors of the disease and supportive treatment. Specifically, the participation in the clinical development of EGFR and ALK inhibitors and immunotherapy agents in lung cancer should be highlighted.

Message Presenter
http://Begoña%20de%20las%20Heras%20Garcia,%20Covance%20Clinical%20Development%20Services

Begoña de las Heras Garcia, MD, Senior Medical Director, Oncology, Covance Clinical Development Services

Dr. Begoña de las Heras Garcia serves as project physician on clients’ drug development projects, oversees three oncology physicians as part of the Covance Medical Consulting Team in Oncology and is building of a global network of sites with expertise in early phase oncology. She brings more than 20 years of national and international clinical oncology research experience and joined Covance in 2016.

She is named as an inventor of two patent applications, according to her contribution to clinical trials and is a member of the Spanish Society of Medical Oncology, European Society of Clinical Oncology, American Society of Clinical Oncology and Madrid Medical School.

Message Presenter

Who Should Attend?

  • Chief Medical Officer
  • Chief Executive Officer
  • Senior Medical Director
  • Medical Director
  • Clinical Development Director
  • Research and Development Director
  • Operational Director
  • Senior Operational Director
  • Clinical Director
  • Senior Clinical Director
  • Research Director
  • Project/Program Managers

What You Will Learn

  • Considerations for adapting clinical and research practice on cancer disease management during the COVID-19 pandemic
  • The scientific rationale for re-tasking oncology drugs for COVID-19 patient treatment
  • Strategies for managing patients and moving beyond the pandemic
  • The role of decentralized clinical trial tools and technologies in clinical practice
  • Expectations for expedited review and accelerated approval for clinical trials related to COVID-19

Xtalks Partner

Covance

Covance is a business segment of LabCorp, a leading global life sciences company, which provides contract research services to the drug, medical device and diagnostics, crop protection and chemical industries. Employing over 21,000 people worldwide, we are the world’s most comprehensive CRO, dedicated to improving health and improving lives.

Covance is a global leader in nonclinical safety assessment, clinical trial testing and clinical trial management services. Our unique perspectives are based on decades of scientific, medical, and regulatory expertise. We generate more safety and efficacy data to support drug approvals than any other company, supporting our clients’ complete lifecycle management.

Together with our clients, Covance transforms today’s healthcare challenges into tomorrow’s solutions. Visit us at www.covance.com.

Media Partner

The original site for employees in the pharma, medical, diagnostic and related industries. Our hand-curated daily news feed and active message forums will keep you informed.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account